StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis YoY Growth in the U.S. by Year

YoY Growth in the U.S. (% USD / cc) (%)

Novartis YoY Growth in the U.S.: 11.0% in FY2025, down 15.0 pts from a year earlier.

Latest, FY2025
11.0%
Period ended Dec 31, 2025
Change on a year earlier
-15.0 pts
26.0% in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Top 20 brands total | 21 154 | 11 | 23 359 | 12 | 11 | 44 513 | 12 | 11”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedYoY Growth in the U.S. (% USD / cc) (%)Year on yearSource
FY2025Dec 31, 202511.0%-15.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 202426.0%+11.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 202315.0%+9.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
FY2022Dec 31, 20226.0%–Novartis Form 6-K (0001370368-23-000008) ↗

Cite this data

StockData. (2026). Novartis YoY Growth in the U.S. (%), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/portfolio-top20-us-yoy-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.